Moleculin biotech, inc. (MBRX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15
Cash flows from operating activities:
Net loss

-1,209

-3,797

-4,146

-1,221

-4,041

-2,785

-2,039

-5,125

-1,927

-3,185

-2,866

-3,425

-329

-1,423

-1,432

-739

-332

-524

-224

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

46

52

50

49

48

41

12

7

8

5

5

4

4

4

1

1

0

0

0

Stock-based compensation

397

382

489

318

348

315

244

339

242

220

268

109

110

115

47

160

2

0

0

Deferred compensation - related party

-

-

-

-

-

-

-

-

-

0

-1

25

38

-1

88

0

0

-

-

Gain from change in fair value of warrant liability

-3,845

-1,003

-123

-2,407

-529

-1,571

-574

-331

-709

-

-

-

-1,059

0

0

0

0

-

-

Operating lease, net of sublease receipts

-99

4

4

6

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain in settlement of liability

-

-

-

-

-

-

-

-

-

0

0

0

149

0

0

0

0

-

-

Shares issued for licenses used for research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-2

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-611

-428

1,670

676

-9

80

-410

536

46

-154

-77

540

55

-30

-70

315

0

-

23

Accounts payable

-947

-1,035

1,931

-1,542

1,553

461

-891

1,105

-239

-106

525

-295

287

-

-

-

-

-

-

Accrued expenses and other current liabilities

506

301

-344

138

-1,235

477

-14

1,073

-136

727

-80

86

-238

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

275

-462

40

259

63

Net cash used in operating activities

-4,342

-4,677

-3,327

-5,347

-3,847

-3,110

-2,819

-3,467

-2,807

-2,390

-1,611

-1,932

-1,391

-

-

-

-

-

-

Accounts payable and accrued expenses - related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

19

Net Cash Used in Operating Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,355

-290

-260

-162

Cash flows from investing activities:
Investment in note receivable - Moleculin, LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30

-

-

Purchase of fixed assets

2

10

8

19

15

114

295

0

8

16

8

4

0

-

-

-

-

0

0

Acquisition of Moleculin, LLC, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash used in investing activities

-2

-9

-8

-19

-15

-114

-295

0

-8

-16

-8

-4

0

-

-

-

-

-

-

Net Cash Used in Investing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30

-30

0

0

Cash flows from financing activities:
Proceeds from exercise of stock options

0

0

0

0

5

5

0

0

0

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of common stock, net of issuance costs

5,291

-

-

-

5,516

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

165

200

250

Payments on notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from exercise of warrants

-

-

-

-

-

0

0

0

15

180

676

2,327

805

-

-

-

0

-

-

Proceeds from sale of common stock, net of issuance costs

-

-

-

-

-

1,756

0

2,069

8,200

-

-

-

-

-

-

8,780

387

1

0

Proceeds from sale of common stock units, net of cash stock issuance costs

-

-

-

-

-

-

-

-

-

-

407

0

4,460

-

-

-

-

-

-

Net cash provided by financing activities

5,291

0

52

15,281

5,521

1,761

0

2,069

8,215

1,384

1,083

2,327

5,265

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-33

12

-3

-2

-11

-3

-8

6

0

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

914

-4,674

-3,286

9,913

1,648

-1,466

-3,122

-1,392

5,400

-

-

-

-

-

-

-

-

-

-

Net Cash Provided by Financing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,310

552

201

250

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-1,022

-536

391

3,874

-1,177

-1,061

6,985

232

-59

87

Supplemental disclosures of cash flow information:
Cash paid for interest

0

0

0

0

1

2

2

0

1

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

0

0

-43

0

48

0

0

0

Cash paid for taxes

6

4

4

9

2

1

5

10

5

0

0

0

0

0

0

0

0

0

0

Non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued liabilities

23

1

0

-20

41

-113

136

0

0

-

-

-

-

-

-

-

-

-

-

Common stock issued for the Acquisition of Moleculin, LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Common stock issued for conversion of debt

-

-

-

-

-

-

-

-

-

0

0

112

190

22

141

201

0

0

0

Common stock issued for services provided

-

-

-

-

-

-

-

-

-

0

0

0

89

158

0

0

0

-

-

Shares subscribed

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

4